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Abstract –
Cell-free protein synthesis (CFPS) is an in vitro protein synthesis system that provides a uniquely
adaptable platform for protein production. In recent years, lyophilization of CFPS have expanded the
capabilities of this system by improving reagent stability outside of cold-chain storage. This project sought
to utilize lyophilized CFPS reagents to develop a convenient, shelf-stable, on-demand therapeutic protein
production platform. The therapeutic protein production potential of this novel platform was demonstrated
by the successful expression of an FDA approved therapeutic protein. With the advancement of shelfstable, on-demand protein therapeutic production platforms comes the potential to provide point-of-care
medical treatment for space-flight crews during long duration missions.

Introduction
As the dream of long-term space exploration
becomes a reality, so do the unique health risks
associated with space flight. Missions requiring
long-duration habitation beyond low-earth orbit
pose significant challenges to the health and
well-being of the crew. Successful medical
interventions,
as
well
as
biomedical
countermeasures to prevent or mitigate high-risk
conditions, are contingent on the therapeutics
available to the crew. Some of the most
beneficial options for medical care are protein
therapeutics, as they provide particularly
effective treatments for cancer, genetic diseases,
neurological disorders, and radiation syndromes.
However, the availability of protein therapeutics
is limited by their low stability under high-levels
of radiation and long term storage [1].
This project sought to overcome the challenges
of protein therapeutic availability during longterm space flight by engineering a lyophilized
cell-free protein synthesis (CFPS) system
capable of producing protein therapeutics on
demand and with minimal equipment; thus,
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providing life-saving treatments to space flight
crews.
Relevance to NASA Aims
This work focuses on supporting Strategic Goal
2 of NASA’s 2018 Strategic Plan which is to
“Extend Human Presence Deeper into Space and
to the Moon for Sustainable Long-term
Exploration and Utilization” [2]. In particular,
this project addresses the specific challenges
identified in the NASA Technology Roadmaps:
pharmaceutical stability under space flight
conditions (TA 6.3.2), and effective treatment
options for high-risk medical conditions for longduration health (TA 6.5.2) [3]. Potentially, many
of these challenges can be addressed through ondemand production of protein therapeutics
during long-term space flight.
Protein therapeutic availability on board
spacecraft can improve treatment options and
countermeasures during interplanetary missions
against cancer, genetic diseases, neurological
disorders, and radiation syndromes (TA 6.5.2.4,
6.5.2.2, 6.5.2.1). However, the availability of
these powerful therapeutics during missions is
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limited by their long-term stability under spaceflight conditions and the difficulty of
determining the therapeutics one will need prior
to take-off. On-demand protein therapeutic
production could eliminate the need to store
protein therapeutics long-term while also
improving the versatility of in-flight biomedical
countermeasures and treatments

Background
Cell-free Protein Synthesis
The production of proteins requires biological
processes as conducted by specialized cellular
machinery. The traditional method of protein
manufacturing produces proteins within living
cell cultures, or in vivo. These cell-based
production platforms are dependent on the
growth and replication of living cells and
therefore require time intensive production,
purification, and protein isolation steps. Protein
therapeutics are conventionally purified and
stored in aqueous or dried form in low
temperature storage until administration.
However, stability of these isolated proteins is
limited over time with elevated temperatures. In
vitro cell-free protein synthesis systems (CFPS)
are an emerging production platform that provide
an alternative approach to conventional protein
production and storage. CFPS platforms
circumvent many of the disadvantages of in vivo
manufacturing and present the capability of ondemand protein therapeutic production.

On-demand protein therapeutic production
through CFPS may enable spaceflight crews to
produce protein therapeutics as the need arises as
opposed to relying on spacecraft inventory which
may be limited by payload restrictions and
therapeutic stability limitations. Protein
therapeutics are most commonly expressed in
vivo; however, cellular systems are not
particularly effective in the space environment
due to cell destruction under ionizing radiation
[4]. These in vivo systems also require a
significant amount of equipment and complex
purification steps. Alternatively, CFPS systems
make it possible to synthesize proteins outside of
a cell by combining the DNA of the protein of
interest with emancipated cellular machinery in a
reaction vessel (Figure 1). Cell-free expression
has been demonstrated on a wide array of
therapeutic proteins including antibodies,
vaccines, and cancer drugs [5]. CFPS technology
facilitates rapid product purification with
minimal equipment and provides an efficient
protein production platform with high protein
yields in as little as an hour which is an order of
magnitude faster than in vivo production [6].
Lyophilization
CFPS provides rapid recombinant protein
production; however, the major components of a
cell free system must be stored in aqueous
solutions below freezing [7]. To ensure protein
synthesis viability, the CFPS solutions are most

Figure 1: Illustration of CFPS: E. Coli cells are lysed for components to be used in a CFPS system for the
production of protein therapeutics or other biocatalysts.
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commonly maintained at -80°C, requiring low
temperature freezers. To overcome this
drawback, lyophilization can be used to preserve
CFPS systems. Lyophilization, or freeze-drying,
is a commonly used preservation technique on
consumables to extend shelf-life, reduce volume
and weight, and lower bacterial contamination.
We can utilize this technique on CFPS systems
with minimal disruption in efficacy as they do not
require living cells. A CFPS system can therefore
be created from lyophilized, shelf-stable reagents
(Figure 4) [8]. These ready-made powdered
CFPS systems are capable of high-density,
thermostable storage with the proven capacity to
produce protein therapeutics [9]. An example of
a stored, small-scale lyophilized CFPS system is
shown in Figure 2.

Figure 2: Image of Lyophilized CFPS system stored in
test tube 6 months at room temperature

Initial lyophilization work using freeze-dried cell
extracts and separate powdered energy systems
demonstrated that the lyophilized systems retain
viability over a 60-day period at room
temperatures [8] and in follow on work has
demonstrated retained activity after 1 year when
stored at 4°C. In comparison, all activity was lost
in the non-lyophilized sample [9]. Additionally,
cryoprotectant additives can be considered for
even greater retention of CFPS activity over
longer storage periods. Initial studies using
cryoprotectant have shown promise for
prolonged storage [10].
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Previous iterations of lyophilized CFPS have
required the cell extract and energy mix to be
stored separately. One reason for this may be the
hydrophobic nature of some of the components
of the energy mix which may decrease its dry
storage capacity. However, separate storage of
the cell extract and energy mix limits the
convenience of the current lyophilized CFPS
systems. A one-pot CFPS platform which only
requires rehydration of water and addition of
DNA template would provide a straightforward,
user-friendly platform. To this aim, this project
sought to optimize lyophilization and
cryoprotectant additives to enhance preservation
of a one-pot CFPS system.
Convenient Downstream Purification
One of the most significant challenges to on-site,
point-of-care
production
is
purification
efficiency and the risk of endotoxin exposure
from incomplete purification of bacteria residue.
Commercial protein therapeutic production relies
on extensive purification and quality control
steps to ensure complete endotoxin removal.
These steps require a high degree of specialized
equipment and personnel training. However, an
on-demand, point-of-care production platform
should be able to produce and purify a protein
therapeutic with minimal equipment and
training. To address this challenge, our lab
recently developed an “endotoxin-free” CFPS
system using a commercial LPS-free cell strain
ClearColi™BL21(DE3) [9]. By eliminating the
source of toxic LPS the risk of endotoxin
exposure during therapeutic administration is
essentially eliminated.
We have demonstrated the use of ClearColi™ in
conventional CFPS systems [11] as well as our
lyophilized on-demand CFPS system [12];
however, the preparation of ClearColi™ extract
required in the CFPS systems remains timeconsuming and labor-intensive because of the
relatively slow growth kinetics of the
ClearColi™ cell strain. This project sought to
develop an improved protocol for the preparation
of ClearColi™ cell extract for CFPS systems.
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Here we report a streamlined procedure for
preparing ClearColi™ cell extract using an autoinduction media (AIM). AIM is an engineered
cell culture media which achieves protein
expression by catabolite repression of the
lacUV5 promoter and eliminates the need for
manual induction of protein expression.
Culturing Clearcoli™ cells in autoinduction
media significantly reduces the hands-on time
required during extract preparation and has
demonstrated improved extract efficacy.

Experimental Methods
CFPS Reactions
CFPS reactions were formulated with 25 vol
percent cell extract, 25 vol percent PANOxSP
energy mix as previously described [13], 12 nM
plasmid DNA, and ultrapure water to volume.
Reaction was incubated 3 h at 37 °C and 120 rpm.
Production yields of super-folder green
fluorescent protein (sfGFP) were determined by
fluorescence at 485/510 excitation/emission
wavelengths according to a standard curve
created by C14-leucine labeled proteins, as
reported previously [7]. Crisantaspase was
expressed for 6.5–8 h at 30 °C and 120 RPM and
yield was determined using C14 labeled leucine
as previously described [7].
Cell Extract Preparation and Lyophilization
Cell-free extracts were prepared from
ClearColi™ BL21 (DE3) strains as described
previously [2]. Briefly, cells were grown in 2.5 L
Tunair flasks (IBI Scientific, Peosta, IA) and
production of T7 RNA polymerase was induced
via addition of 1mM IPTG during early
exponential growth. Cells were harvested in mid
log phase by centrifugation at 6000 rcf for 10
min. Cells were homogenized at 21,000 psig in
an Avestin French Press. Prior to lyophilization,
cryoprotectants were added to cell extract
samples as specified in Table 1 [12].
Additionally, the energy system PANOxSP[13]
was added to the samples prior to lyophilization.
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Table 1
Cryoprotectant content and concentrations [12]

Samples were frozen in a -40°C ethanol bath
(Just-A-Tilt Shell Freezer Chiller SF-4Az, FTS
Systems, Warminster, PA). Samples were then
lyophilized (Flexidry MP, FTS Systems). After
approximately 1.5 hours of freeze-drying,
samples reached minimum weight suggesting
samples were sufficiently dried.
Lyophilized CFPS systems were stored at 4°C,
25°C, 37°C, and 50°C for 90 days and tested
periodically for protein synthesis activity.
Activity was determined by measuring
production yields of sfGFP. To demonstrate the
capacity of this system to produce protein
therapeutics, the FDA approved cancer
therapeutic crisantaspase was also produced after
46 days of storage.
Streamlined Endotoxin-free CFPS
Preparation
AIM induction kinetics were investigated to
determine optimal cell culture fermentation.
Auto-induction media was adapted from the
“ZYM-5052” protocol reported by Studier [29].
1 mL overnight culture of BL21 Star™(DE3),
and BL21 Star™(DE3)-pY71-sfGFP were was
added to 100 mL AIM with either 0.05 or 1% w/v
final glucose concentrations. Cultures were
fermented at 37°C and 280 rpm. Absorbance
(OD600) of cultures were read 2 or 3 times per
hour for 12 h. Simultaneously, fluorescence of
100 μl of cell culture were measured with
Synergy-MX Multi-Plate Reader (Biotek,
Winooski, VT). ClearColi™ BL21(DE3) growth
and induction kinetics were assessed similarly
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except OD600 and culture fluorescence were
measured once per hour for 15 h.
After AIM induction kinetics were elucidated,
the efficacy of cell extract produced by AIM was
tested. ClearColi™ was fermented in 1.5 L AIM
prepared to 0.05% final glucose concentration in
2.5 L Tunair shake flasks. Cultures were
fermented at 37 °C and 280 rpm. ClearColi™ cell
culture was harvested at 5.4 h (OD600 = 1.0), 7.7
h (OD600 = 3), and 9.8 h (OD600 = 7.0) of
fermentation. Cells were homogenized as
described above. As with the lyophilized extract,
AIM prepared ClearColi™ extract was tested by
measuring production levels of sfGFP protein.
Similarly, to demonstrate the capacity of this
system to produce protein therapeutics, the FDA
approved therapeutic
crisantaspase
was
produced.

Results
This project advanced on-demand CFPS systems
capable of producing yields appropriate for
therapeutic doses. We have achieved an
improved lyophilized, endotoxin-free CFPS
system from those previously reported by our lab
and others. For on-demand CFPS protein
production, this new system only requires
rehydration with water and the addition of the
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DNA template of choice. Additionally, the
preparation of the endotoxin-free cell extract was
optimized for improved preparation efficiency
and extract efficacy.
The lyophilized, on-demand CFPS system held
activity after storage at elevated temperatures.
Samples containing cryoprotectants showed
prolonged activity over that of the control system
as presented in Figure 3A. The potential of using
these lyophilized CFPS systems for protein
therapeutic production was demonstrated by the
production of the FDA-approved cancer
therapeutic crisantaspase. Active crisantaspase
was produced at significant yields after 46 days
of storage at elevated temperatures (Figure 3B).
The promising results of our novel lyophilized
on-demand CFPS system demonstrated a viable
shelf-stable, one-pot CFPS system utilizing
endotoxin-free ClearColi™ cell extract.
The promising results from this study prompted
further research into optimizing the preparation
of the ClearColi™ cell extract. We demonstrated
a streamlined procedure for preparing
ClearColi™ cell extract using AIM. This new
protocol still requires a greater amount of time
than that of traditional BL21 Star (DE3) as shown
by the growth kinetics in Figure 4A; however, it
significantly reduces required hands-on time. In

B

Figure 3: A) sfGFP yields after storage at 4°C, 25°C, 37°C, and 50°C from CFPS systems lyophilized with and without
cryoprotectants. Sample combinations are described in Table 1. Extract only sample was not lyophilized with PANOxSP; B)
Crisantaspase yields from CFPS system lyophilized with Dextran cryoprotectant after 46 days of storage.
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The performance of ClearColi™ cell extracts
prepared by AIM were further tested by
producing the protein therapeutic crisantaspase.
AIM prepared ClearColi™ proved to maintain
the same cell-free protein synthesis capability as
extract produced with traditional fermentation
and induction methods as demonstrated by the
high-yield expression of crisantaspase as shown
Figure 4C. These results suggest that preparing
ClearColi™ cell extract with AIM is superior to
that of traditional preparation methods as it is
significantly more efficient while still
maintaining equivalent-yielding CFPS.

Figure 4: A) Kinetic growth curves (OD600) and harvest
times of BL21 Star™(DE3) and ClearColi™ cells
prepared in AIM; B) CFPS sfGFP expression yield from
ClearColi™ cell extract prepared using AIM as
compared to sfGFP yield from ClearColi™ cell extract
prepared using traditional fermentation and induction
method; C) Crisantaspase yields using ClearColi™ cell
extract prepared with AIM compared to yields using
traditional fermentation and induction methods.

particular, AIM reduces the need to monitor the
cells throughout growth and eliminates manual
induction. We report that the optimal time to
harvest ClearColi™ to obtain cell extract for
high-yielding CFPS is at early to mid-log phase
which equates to ~5.5-8 h after initial cell
inoculation. Even waiting 10 h after initial cell
inoculation still resulted in decent protein
expression yields in CFPS (See Figure 4B for
protein expression yields at different harvest
times). These results suggest that not only does
AIM simplify preparation procedures but also
allows for more flexibility in the timing of
harvest.
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A full disclosure and extended discussion of the
experimental methods and results of this project
are documented in the articles: 1) “Thermostable
lyoprotectant-enhanced
cell-free
protein
synthesis for on-demand endotoxin-free
therapeutic production” (New BioTechnology),
and
2) “Streamlining the preparation of
‘endotoxin-free’ ClearColi cell extract with
autoinduction media for cell-free protein
synthesis
of
the
therapeutic
protein
crisantaspase”
(Synthetic
and
Systems
Biotechnology).

Conclusion
Lyophilization, of cell-free systems creates rapid
protein synthesis systems that can be created in
mass and stored for later use on an on-demand
basis. This ready-made powdered CFPS provides
high density and non-standard temperature
storage
improving
the
overall
cost,
transportability, and convenience of a CFPS
system. Additionally, this unique CFPS system
utilizes an endotoxin-free cell extract which
eliminates
costly
and
time-consuming
purification steps.
This work constitutes an important study for the
design of lyophilized CFPS systems for
prolonged storage by demonstrating the robust
nature and therapeutic production capacity of an
on-demand protein production platform.
Significant progress has been made towards the
development of practical on-demand CFPS
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systems for therapeutic protein production during
long-term space flight. The advancements made
through this project are particularly important in
streamlining the production of protein therapetics
outside of commercial centralized facilities. In
particular, we have simplified the fermentation
process of the cell extract, improved CFPS longterm storage, and eliminated endotoxin removal
steps. Figure 4 summarizes these advancements.

Figure 4: Steps associated with protein therapeutic production through commercial manufacturing (top) and the novel CFPS ondemand , endotoxin-free system described in this work (bottom).
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